bavarian blue
Selected indexed studies
- The contemporary management of prostate cancer. (CA Cancer J Clin, 2025) [PMID:40572035]
- Next generation radiotheranostics promoting precision medicine. (Ann Oncol, 2023) [PMID:36924989]
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. (Lancet Oncol, 2023) [PMID:37714168]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. (2023) pubmed
- TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. (2021) pubmed
- The contemporary management of prostate cancer. (2025) pubmed
- Next generation radiotheranostics promoting precision medicine. (2023) pubmed
- Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. (2024) pubmed
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. (2021) pubmed
- Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. (2023) pubmed
- Advances in Targeted Therapy for Metastatic Prostate Cancer. (2025) pubmed
- Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. (2024) pubmed
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. (2021) pubmed